Observational studyNeurology2017
MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
Observational study in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00176592 (Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Imaging cortical multiple sclerosis lesions with ultra-high field MRI.NeuroImage. Clinical · 2021Pooled it
- Delayed transcallosal conduction to the lesioned sensorimotor cortex in multiple Sclerosis: A combined TMS 7 T-MRI study.NeuroImage. Clinical · 2026Article
- Demyelinated lesion associated compartmental inflammation in progressive multiple sclerosis brains.Acta neuropathologica communications · 2025Article
- Cortical lesions are common in a longitudinal progressive multifocal leukoencephalopathy cohort.Brain communications · 2025Article
- The influence of MOGAD on diagnosis of multiple sclerosis using MRI.Nature reviews. Neurology · 2024Review
- Imaging blood-brain barrier disruption in neuroinflammation and Alzheimer's disease.Frontiers in aging neuroscience · 2023Review
- Microglia-derived CCL2 has a prime role in neocortex neuroinflammation.Fluids and barriers of the CNS · 2022Article
- Significant higher-level C-C motif chemokine ligand 2/3 and chemotactic power in cerebral white matter than grey matter in rat and human.The European journal of neuroscience · 2021Article
- Inflammatory mechanisms underlying cortical injury in progressive multiple sclerosis.Neuroimmunology and neuroinflammation · 2021Article
- Association Between Magnetic Resonance Imaging-Based Spinal Morphometry and Sensorimotor Behavior in a Hemicontusion Model of Incomplete Cervical Spinal Cord Injury in Rats.Brain connectivity · 2020Article
- Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI.AJNR. American journal of neuroradiology · 2019Article
- Blood-Brain Barrier: From Physiology to Disease and Back.Physiological reviews · 2019Review
- The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?Journal of neurology · 2018Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify gadolinium-enhancing lesions affecting the cortex of patients with early multiple sclerosis (MS) and to describe the frequency and evolution of these lesions.
methodsWe performed a retrospective, observational, longitudinal analysis of MRI scans collected as part of the Betaseron vs Copaxone in Multiple Sclerosis with Triple-Dose Gadolinium and 3T MRI Endpoints (BECOME) study. Seventy-five patients with early-stage MS were scanned monthly, over a period of 12-24 months, using 3T MRI after administration of triple-dose gadolinium. A total of 1,188 scans were included in the analysis. A total of 139 were selected using an image pipeline algorithm that integrated the image information from cortical gray matter masks and gadolinium-enhancing lesion masks. These scans were evaluated to identify gadolinium-enhancing lesions affecting the cortex.
resultsThe total number of gadolinium-enhancing lesions was 2,044. The number of gadolinium-enhancing lesions affecting the cortex was 120 (6%), 95% of which were leukocortical. The number of patients who showed gadolinium-enhancing lesions affecting the cortex was 27 (36%). The number of gadolinium-enhancing lesions affecting the cortex at baseline was 25 (21%) and the number of new lesions that developed in follow-up scans was 49 (41%). The number of persistent lesions was 46 (38%).
conclusionsThe presence of enhancing lesions affecting the cortex and adjacent white matter, although transient and not frequent, suggests that at least some cortical lesions are related to blood-brain barrier disruption. Our data support the concept that there may be an acute inflammatory phase in the development of leukocortical MS lesions. CLINICALTRIALSGOV IDENTIFIER: NCT00176592.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.